Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modulation of Liver Inflammation and Fibrosis by Interleukin-37.
Mountford S, Effenberger M, Noll-Puchta H, Griessmair L, Ringleb A, Haas S, Denk G, Reiter FP, Mayr D, Dinarello CA, Tilg H, Bufler P. Mountford S, et al. Among authors: haas s. Front Immunol. 2021 Mar 4;12:603649. doi: 10.3389/fimmu.2021.603649. eCollection 2021. Front Immunol. 2021. PMID: 33746950 Free PMC article.
Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.
Macht A, Huang Y, Reinert LS, Grass V, Lohmer K, Aristizabal Prada ET, Babel E, Semmler A, Zhang W, Wegner A, Lichtenegger-Hartl E, Haas S, Hasenpusch G, Meyer S, Paludan SR, Pichlmair A, Rudolph C, Langenickel T. Macht A, et al. Among authors: haas s. EMBO Rep. 2024 Sep;25(9):3777-3788. doi: 10.1038/s44319-024-00216-4. Epub 2024 Jul 26. EMBO Rep. 2024. PMID: 39060455 Free PMC article.
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Loibl S, et al. J Clin Oncol. 2024 Sep 11:JCO2302505. doi: 10.1200/JCO.23.02505. Online ahead of print. J Clin Oncol. 2024. PMID: 39259927
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, Röthemeier C, Neuber B, Hückelhoven-Krauss A, Brüggemann M, Bernhard H, Kobbe G, Lindemann A, Rummel M, Michels B, Korell F, Ho AD, Müller-Tidow C, Schmitt M. Derigs P, et al. Among authors: haas s. Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392-7. Online ahead of print. Leukemia. 2024. PMID: 39192036
1,459 results